Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPHENE 65 vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Relief of mild to moderate pain,FDA-approved for pain management (withdrawn due to cardiac toxicity)
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life of propoxyphene: 6-12 hours (mean ~8 hours); norpropoxyphene half-life: 22-36 hours, leading to accumulation with chronic dosing. Clinical context: prolonged half-life in elderly and hepatic impairment increases risk of toxicity.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Hepatic via CYP3A4 and CYP2D6 to norpropoxyphene (active metabolite with longer half-life). Minor metabolism via N-demethylation and glucuronidation.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Renal elimination of unchanged drug and metabolites: propoxyphene and its major metabolite norpropoxyphene account for ~20-30% as unchanged drug in urine; remainder as conjugated metabolites. Biliary/fecal elimination accounts for <10%.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Propoxyphene: ~78% bound to albumin; norpropoxyphene: ~95% bound to albumin.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Volume of distribution: 16-20 L/kg (suggesting extensive tissue binding). Clinical meaning: high Vd indicates wide distribution into tissues, contributing to long half-life and potential for accumulation.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: approximately 30-70% (first-pass metabolism). Other routes: not formulated for parenteral use.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
Cr Cl < 30 m L/min: Avoid use due to accumulation of toxic metabolite norpropoxyphene. Cr Cl 30-50 m L/min: Reduce dose to 50 mg every 6 hours.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh Class C: Contraindicated. Child-Pugh Class B: Avoid use or reduce dose by 50% with close monitoring.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Not recommended for use in pediatric patients due to risk of respiratory depression and lack of established safety.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Initiate at lowest dose (e.g., 50 mg every 6 hours) and titrate cautiously; avoid in patients with renal impairment or concomitant CNS depressants.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
WARNING: RISK OF CARDIAC TOXICITY AND OVERDOSE. Propoxyphene has been withdrawn from the US market due to risk of fatal cardiac arrhythmias (QT prolongation, torsade de pointes) even at therapeutic doses. Use with alcohol or other CNS depressants increases risk of respiratory depression and death.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Cardiac toxicity (QT prolongation, torsade de pointes); respiratory depression; CNS depression (additive with alcohol/other depressants); risk of abuse and dependence; renal or hepatic impairment; elderly patients; history of head injury; increased intracranial pressure; seizure disorders; acute abdominal conditions.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to propoxyphene or opioid cross-sensitivity; known QT prolongation; concurrent use of MAO inhibitors; severe asthma or respiratory depression; obstructive airway disease; paralytic ileus; pregnancy and breastfeeding.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
No specific food interactions; avoid excessive grapefruit juice as it may increase propoxyphene levels.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trimester: Limited data; potential for oligohydramnios. Third trimester: Premature closure of ductus arteriosus, fetal renal dysfunction with oligohydramnios, and neonatal pulmonary hypertension. Avoid in third trimester unless compelling need.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Excreted into breast milk in small amounts; M/P ratio approximately 0.7. Clinical studies show no adverse effects in infants at therapeutic maternal doses. However, due to potential for prostaglandin inhibition, caution is advised, especially in premature infants or those with platelet dysfunction. Consider monitoring infant for bruising, bleeding, or gastrointestinal effects.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No standard dose adjustment recommended for pregnancy. However, due to increased volume of distribution and renal clearance in pregnancy, lower plasma concentrations may occur. Clinical efficacy should guide therapy; dosing at the lower end of the recommended range (e.g., 325 mg every 4-6 hours) is prudent to minimize fetal exposure. Avoid high doses and chronic use in third trimester.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
Propoxyphene is a weak opioid analgesic; avoid in patients with suicidal ideation or history of substance abuse due to risk of overdose and cardiac toxicity (QT prolongation). Use with caution in elderly and renal impairment; start at lower doses. Monitor for respiratory depression, especially when combined with CNS depressants.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Take exactly as prescribed; do not increase dose or frequency.,Do not consume alcohol or other CNS depressants.,May cause dizziness or drowsiness; avoid driving until known effect.,Report any signs of allergic reaction or irregular heartbeat.,Do not stop abruptly; withdrawal symptoms may occur.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPHENE 65 vs ALFENTANIL, answered by our medical review team.
PROPHENE 65 is a Opioid Analgesic that works by Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPHENE 65 and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPHENE 65 is: Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPHENE 65 and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPHENE 65 is classified as Category C. FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trime. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.